| 1 |
Su Q, Hua F, Xiao W, Liu B, Wang D, Qin X. Investigation of Hippo pathway-related prognostic lncRNAs and molecular subtypes in liver hepatocellular carcinoma. Sci Rep 2023;13:4521. [PMID: 36941336 DOI: 10.1038/s41598-023-31754-x] [Reference Citation Analysis]
|
| 2 |
Li HX, Wang SQ, Lian ZX, Deng SL, Yu K. Relationship between Tumor Infiltrating Immune Cells and Tumor Metastasis and Its Prognostic Value in Cancer. Cells 2022;12. [PMID: 36611857 DOI: 10.3390/cells12010064] [Reference Citation Analysis]
|
| 3 |
Su Q, Li L, Li X, Li W, Zhang X, Dong Y, Han L, Wang D, Ran J. CD97 serves as a novel biomarker of immune cell infiltration in hepatocellular carcinoma. World J Surg Oncol 2022;20:382. [PMID: 36464675 DOI: 10.1186/s12957-022-02829-2] [Reference Citation Analysis]
|
| 4 |
Su Q, Hua F, Xiao W, Liu B, Wang D, Qin X. Investigation of Hippo pathway-related prognostic lncRNAs and molecular subtypes in liver hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2284692/v1] [Reference Citation Analysis]
|
| 5 |
Gedaly R, Cornea V, Turcios L, Edmisson JS, Harris DD, Watt DS, Chapelin F, Khurana A, Mei X, Liu C, Taylor I, Gonzalez-Valdivieso J, Mitchel H, Ruffing A, Chishti A, Orozco G, Zwischenberger J, Evers BM, Marti F. Anti-neoplastic sulfonamides alter the metabolic homeostasis and disrupt the suppressor activity of regulatory T cells. Sci Rep 2022;12:19112. [PMID: 36352020 DOI: 10.1038/s41598-022-23601-2] [Reference Citation Analysis]
|
| 6 |
Sharafi F, Hasani SA, Alesaeidi S, Kahrizi MS, Adili A, Ghoreishizadeh S, Shomali N, Tamjidifar R, Aslaminabad R, Akbari M. A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review. Cancer Cell Int 2022;22:269. [PMID: 35999569 DOI: 10.1186/s12935-022-02682-z] [Reference Citation Analysis]
|
| 7 |
Zhang CY, Liu S, Yang M. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World J Gastroenterol 2022; 28(27): 3346-3358 [DOI: 10.3748/wjg.v28.i27.3346] [Reference Citation Analysis]
|
| 8 |
Chen C, Wu Y, Chen K, Xia Z, Liu X, Zhang C, Zhao H, Shen A. Identification and Validation of Necroptosis-Related LncRNA Signature in Hepatocellular Carcinoma for Prognosis Estimation and Microenvironment Status. Front Genet 2022;13:898507. [PMID: 35754846 DOI: 10.3389/fgene.2022.898507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Bahcivanci B, Shafiha R, Gkoutos GV, Acharjee A. Associating transcriptomics data with inflammatory markers to understand tumour microenvironment in hepatocellular carcinoma. Cancer Med 2023;12:696-711. [PMID: 35715992 DOI: 10.1002/cam4.4941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Fang W, Gan Y, Zhang L, Xiong J. COMMD2 Upregulation Mediated by an ncRNA Axis Correlates With an Unfavorable Prognosis and Tumor Immune Infiltration in Liver Hepatocellular Carcinoma. Front Oncol 2022;12:853026. [DOI: 10.3389/fonc.2022.853026] [Reference Citation Analysis]
|
| 11 |
Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 12 |
Zheng X, Jin W, Wang S, Ding H. Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:729705. [PMID: 34566989 DOI: 10.3389/fimmu.2021.729705] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 13 |
Borensztejn K, Tyrna P, Gaweł AM, Dziuba I, Wojcik C, Bialy LP, Mlynarczuk-Bialy I. Classification of Cell-in-Cell Structures: Different Phenomena with Similar Appearance. Cells 2021;10:2569. [PMID: 34685548 DOI: 10.3390/cells10102569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 14 |
Sanceau J, Gougelet A. Epigenetic mechanisms of liver tumor resistance to immunotherapy. World J Hepatol 2021;13:979-1002. [PMID: 34630870 DOI: 10.4254/wjh.v13.i9.979] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 15 |
Zhou D, Luan J, Huang C, Li J. Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe? Gut Liver 2021;15:500-16. [PMID: 33087588 DOI: 10.5009/gnl20223] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 16 |
Zientarska A, Kaczmarek M, Mozer-Lisewska I, Kowala-Piaskowska A, Witkowska A, Żeromski J. Treg cells in the course of chronic hepatitis C virus infection partially normalize in longitudinal observation after successful DAA treatment regardless of hepatic fibrosis stage. Clin Exp Hepatol 2021;7:196-204. [PMID: 34295988 DOI: 10.5114/ceh.2021.107122] [Reference Citation Analysis]
|
| 17 |
Gonzalez-Sanchez E, Vaquero J, Férnandez-Barrena MG, Lasarte JJ, Avila MA, Sarobe P, Reig M, Calvo M, Fabregat I. The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma? Cancers (Basel) 2021;13:3248. [PMID: 34209646 DOI: 10.3390/cancers13133248] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 18 |
Aghabi YO, Yasin A, Kennedy JI, Davies SP, Butler AE, Stamataki Z. Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer. Front Immunol 2021;12:662134. [PMID: 33953725 DOI: 10.3389/fimmu.2021.662134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 19 |
Bozward AG, Warricker F, Oo YH, Khakoo SI. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. Front Immunol 2021;12:643310. [PMID: 33995362 DOI: 10.3389/fimmu.2021.643310] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 20 |
Liu SD, Zhong LP, He J, Zhao YX. Targeting neuropilin-1 interactions is a promising anti-tumor strategy. Chin Med J (Engl) 2020;134:508-17. [PMID: 33177389 DOI: 10.1097/CM9.0000000000001200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
Abd El Aziz MA, Facciorusso A, Nayfeh T, Saadi S, Elnaggar M, Cotsoglou C, Sacco R. Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines (Basel) 2020;8:E616. [PMID: 33086471 DOI: 10.3390/vaccines8040616] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 22 |
Amada E, Fukuda K, Kumagai K, Kawakubo H, Kitagawa Y. Soluble recombinant human thrombomodulin suppresses inflammation-induced gastrointestinal tumor growth in a murine peritonitis model. Mol Cell Biochem 2020;475:195-203. [PMID: 32767229 DOI: 10.1007/s11010-020-03872-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 23 |
Sachdeva M, Arora SK. Prognostic role of immune cells in hepatocellular carcinoma. EXCLI J 2020;19:718-33. [PMID: 32636725 DOI: 10.17179/excli2020-1455] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
|
| 24 |
Jayant K, Habib N, Huang KW, Podda M, Warwick J, Arasaradnam R. Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines (Basel) 2020;8:E247. [PMID: 32456200 DOI: 10.3390/vaccines8020247] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
